Business Context and Reporting Period
SeaStar Medical Holding Corporation (ICU) filed a Form 8-K on June 6, 2024, reporting a significant capital structure event involving the redemption and conversion of convertible notes held by an institutional investor ("Investor D"). The filing notes that all share amounts are presented in pre-split quantities, with post-split amounts (following a 25-for-1 reverse stock split effective June 7, 2024) shown in parentheses.
Key Financial Metrics and Transaction Details
- Note Redemption: The Company redeemed $0.7 million of outstanding Investor D convertible notes, including accrued interest and make-whole amounts.
- Note Conversion: Investor D converted approximately $0.6 million in unpaid principal and $0.7 million in unpaid interest/make-whole amounts into equity.
- Conversion Terms: Both redemption and conversion were executed at 200% of the Conversion Amount as per the note terms.
- Equity Issuance: The conversion resulted in the issuance of 2,321,429 shares (92,858 post-split shares) of common stock.
- Outstanding Warrants: Investor D retains warrants to purchase approximately 3,158,086 shares (126,323 post-split) with a weighted-average exercise price of $0.55 ($13.75 post-split).
- Debt Status: As of June 6, 2024, no additional Investor D Notes remain outstanding.
Material Changes
The primary material change is the complete elimination of the specific convertible note obligation to Investor D, originally issued on December 11, 2023. This transaction reduced the Company's debt load while simultaneously increasing its share count. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period, as this is a current report on a specific event rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the execution of the note terms. The transaction was conducted in accordance with a previously granted right to redeem and convert at a premium (200% of the Conversion Amount), which represents a significant cost of capital for this specific debt instrument.
Investor Verification Checklist
- Verify the impact of the 25-for-1 reverse stock split on the total share count and per-share metrics.
- Confirm the total cash outflow required for the $0.7 million redemption versus the equity dilution from the conversion.
- Review the remaining debt obligations of the Company to assess overall leverage post-transaction.
- Assess the dilution impact of the 2,321,429 newly issued shares relative to the pre-transaction outstanding share count.
- Check the status of the remaining warrants held by Investor D and their potential exercise impact.